Navigation Links
Lilly Reports Third-Quarter 2011 Results
Date:10/20/2011

>"In the third quarter Lilly continued to drive revenue growth for many key brands, including Cymbalta, Humalog, Forteo and Strattera, with strong growth also seen in animal health, Japan and China. This growth offset the continued erosion of Gemzar sales due to generic competition," said John C. Lechleiter, Ph.D., Lilly's chairman, president and chief executive officer. "As we face the loss of patent exclusivity for Zyprexa in most major markets, we are well-prepared as a company to meet the challenges before us. We remain committed to our innovation-based strategy and are focused on delivering the next wave of new medicines to patients in the coming years."

Key Events Over the Last Three Months

  • The European Commission granted marketing authorization for Trajenta® for the treatment of adults with type 2 diabetes. The company and its partner Boehringer Ingelheim have recently begun launching Trajenta in the European Union, beginning with the United Kingdom.

  • The U.S. Food and Drug Administration (FDA) approved Cialis® tablets for once daily use for the treatment of men who have both erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia (ED+BPH). The FDA also approved Cialis for once daily use for a separate indication for the treatment of the signs and symptoms of BPH.

  • The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for the use of Alimta® as continuation maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer (NSCLC).

  • The U.S. Court of Appeals for the Federal Circuit overturned a prior ruling by the U.S. District Court for the District of New Jersey and upheld the validity of the company's method-of-use patent on Strattera®. The method-of-use patent provides protection for Strattera through May of 2017.

  • The company, along with its partners Amylin Pharmaceutic
    '/>"/>

  • SOURCE Eli Lilly and Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. Lilly Declares Fourth-Quarter 2011 Dividend
    2. Lilly Announces Changes in Senior Management
    3. Lilly Confirms Date and Conference Call for Third-Quarter 2011 Financial Results Announcement
    4. Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities
    5. Eli Lilly and Company Bringing Diabetes Education Program to the Annual Legislative Conference
    6. Lilly Celebrates 17th Consecutive Year as One of Working Mother 100 Best Companies
    7. Lilly Health Channel Debuts on YouTube
    8. Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
    9. The American Diabetes Association and Eli Lilly and Company Encourage African Americans to Learn About Diabetes Through a Familiar Face
    10. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
    11. U.S. Court of Appeals Affirms Validity of Lillys Strattera Patent
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
    (Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
    (Date:1/14/2014)... Jan. 14, 2014 Animal Emergency Critical Care, a LifeCentre partner ... Virginia is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is ... husband, Dr. Cole Taylor , are avid scuba divers. "As ...
    Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
    ... Center is,seeking local residents with type 2 diabetes ... study evaluating an investigational,device, the TANTALUS System. Diabetes ... TANTALUS System is an implantable device that delivers ... The primary objective of the,randomized, double-blind controlled study ...
    ... successfully targets human leukemic stem cells, ATLANTA, ... has today presented data at the American Society,of ... promising,pre-clinical activity of a novel monoclonal antibody, in ... AML is an aggressive cancer of white blood ...
    Cached Medicine Technology:Vanderbilt Medical Center Seeks Middle Tennesseans with Type 2 Diabetes Who are Overweight for National Clinical Trial 2Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML) 2Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML) 3
    (Date:4/18/2014)... by Northwestern Medicine scientists could lead to potential new ... people with scleroderma. , Fibrosis, or scarring, is ... the skin and lungs can lead to serious organ ... for new therapeutic options centers on findings made by ... identified the role that a specific protein plays in ...
    (Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
    (Date:4/17/2014)... published today in PLOS Pathogens , children who ... common can mount an immune response to infection with ... bouts of high fever and illness and partially control ... findings may help researchers develop future interventions that prevent ... , Each year, approximately 200 million cases of malaria ...
    (Date:4/17/2014)... Two recent papers by a University of ... help scientists develop treatments or vaccines for Dengue ... and other disease-causing flaviviruses. , Jeffrey S. Kieft, ... at the School of Medicine and an early ... and colleagues recently published articles in the scholarly ...
    (Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
    Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2
    ... of Western Ontario has received over $603,000 from the Canadian ... a group of bacterial toxins leads to the development of ... is an associate professor in the Department of Microbiology and ... a scientist with the Lawson Health Research Institute. His ...
    ... (UV) radiation from sunlight may be associated with the ... to a study by researchers at the National Institute ... Institutes of Health. "This study found that women ... exposure when they developed an autoimmune muscle disease called ...
    ... July 30, 2009 Scientists at Washington University School ... in the liver that helps process fat and glucose. ... additive lecithin, and researchers speculate it may one day ... lipids and reduce risk for diabetes, hypertension or cardiovascular ...
    ... , , , ... $230,000 for Augie,s Quest, the fast-track research arm of the Muscular Dystrophy ... is dedicated to beating the previous goal by reaching $300,000 in donations ... Bally club now through August 31 and receive a free guest pass ...
    ... more apt to have joint replacement, study finds , THURSDAY, ... strongly predict the risk of hip and knee joint replacement ... , The research involved 912 healthy people in Italy, including ... or hip replacement between 1990 and 2005. Those with high ...
    ... , , , ... Mark Rodgers today announced that The Guardian House Alzheimer Care Facility ... commercial location to install the SamarionSolution, The Guardian House is a ... in caring for residents diagnosed with Alzheimer,s or dementia. The ...
    Cached Medicine News:Health News:Sun exposure may trigger certain autoimmune diseases in women 2Health News:Food additive may one day help control blood lipids and reduce disease risk 2Health News:Food additive may one day help control blood lipids and reduce disease risk 3Health News:Bally Total Fitness Flexes Fundraising Muscle to Fight ALS 2Health News:Biomarker Could Predict Severe Osteoarthritis 2Health News:The First SamarionSolution Installed in Lake Charles Alzheimer's Facility 2
    ... An ISI technician carefully inspects your equipment ... any and all problems, and provides you with ... may be working within a tight budget so ... the intricate work of repair begins., , ISI ...
    ... ALT (GPT) powder reagent is intended for ... in serum. , Infinity ALT (GPT) powder ... stability once reconstituted and convenience, but ensures ... The reagent is suitable for manual use ...
    ... is a fully automated, versatile analyzer ... is increased due to the continuous loading ... A fully graphical user interface provides fast ... use. Konelab analyzers are delivered with full ...
    Inquire...
    Medicine Products: